Funded Projects
FOCUS Competition
       |
       |
       |
2012 Funded Project
Richard Hoge |
Quantitative O2 MRI: a new window on mitochondrial dysfunction in Alzheimer's Disease |
2011 Funded Projects
Michel Bergeron |
Selectomics to monitor and predict the emergence of resistance to antibiotics This new approach will use the human intestinal
microbiome to predict the emergence of The developed tools will permit to evaluate the potential of new chemical compounds to select the resistance. |
|
Jocelyn Dupuis |
PulmoBind: a new non-invasive marker for the early diagnosis of patients with pulmonary hypertension This project is aimed at evaluating in human
subjects PulmoBind, a novel marker that can This non-invasive test will allow to establish an early and effective diagnosis of subjects suffering from pulmonary hypertension and to evaluate the disease progression. |
|
Sylvain Martel |
Magnetically guided drug delivery platform based on bio-carriers for the treatment of colorectal cancer This innovative approach, based on special bacteria that can be directed by a magnetic field, will enable targeted therapeutic intervention at the tumor site. The proof-of-concept of this new technology will be performed using a cancer-fighting drug encapsulated in liposomes in colorectal cancer models. |
|
Morag Park |
Integrated tumour-microenvironment biomarkers for improved targeting of breast cancer therapy The aim of this project is to develop enabling
tools for better stratification of breast cancer |
|
2010 Funded Projects
Emanuel Escher |
A new biosensor paradigm for continuous detection of multiple analytes This new generation of miniature biosensors will be designed to monitor in real time several analytes simultaneously in living animals. A first application will be developed for glucose and insulin measurements. This technology could then be applicable to numerous therapeutic fields. |
|
Michel Maziade |
Profiling of patients with major psychiatric disorders using electroretinography This technology, based on the response of the retina to light stimulation, will allow to accurately and non-invasively stratify patients with majorpsychiatric disorders and to measure the pharmacological response to specific treatments. |
|
Matthias Götte |
A novel phage-based screening technology for antiviral This approach will bring a new highly sensitive assay platform to reduce time and costs associated with screening of antiherpetic compounds. |
|
Gordon Shore |
Integrated platform to identify synthetic lethality opportunities in cancer therapy The proposed platform will allow the identification of cellular pathways and gene targets acting in synergy with new or existing drugs for cancer therapy. This platform could also generate novel biomarkers to predict treatment response through personalized medicine. |
|
2009 Funded Projects
Louis-Philippe |
VLPExpress: a novel, high-throughput technology to accelerate the discovery and development of new vaccine antigens based on Virus-Like Particles (VLPs) Development of VLPExpress, a novel high-throughput platform for the discovery of new Virus-Like Particles (VLPs) vaccine antigen. The ultimate goal is to perform a typical project from target screening to VLP delivery for efficacy testing in about 10 weeks and for less than $100,000. |
|
Michel Bouvier (Université de Montréal) |
Multiplexed biosensors for identifying and monitoring cellular events associated with drugs therapeutic efficacies and side effects Development of new biosensors and bioinformatic tools to dissect the multiple signalling pathways engaged by G protein coupled receptors (GPCRs) in response to ligand binding. This will help to establish the signalling signature to predict drug activity and side effects. |
|
Eustache Paramithiothis |
Development of biomarkers for measurement of early stage diabetes disease and for prediction of response to therapy Relying on Caprion’s CellCarta proteomics technology to develop panels of protein diabetes biomarkers, this project will improve early diagnosis and monitor disease progression, as well as, evaluate therapeutic response |
|
